FDA Commissioner Defends Drug Approval Decisions Amid Backlash
FDA Commissioner Marty Makary defended the agency's recent drug rejections in an interview with CNBC, citing independent reviews and rejecting claims of bias. The controversy includes the rejection of a melanoma drug candidate from Replimune, which the company claims was unfair. Makary emphasized his commitment to public health over corporate interests.
Tickers: $REPL
Topics: drug approval FDA Marty Makary regulatory controversy Replimune